![]() ![]() Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. ![]() The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. ![]() ("Spectrum Acquisition") was less valuable than Assertio had represented to investors and (iii) accordingly, Assertio had overstated the positive impact the sale of Indocin products and the Spectrum Acquisition were likely to have on Assertio's profitability.įor additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at or (267) 637-3176, or Andrew Abramowitz at or (215) 875-3015 or CLICK HERE.Ī lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The complaint alleges that, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Assertio's reliance on Indocin products to boost its net income was unsustainable given the risk of generic competition (ii) Assertio's acquisition of Spectrum Pharmaceuticals, Inc. Investors who purchased or acquired Assertio securities during the Class Period may, no later than March 5, 2024, seek to be appointed as a lead plaintiff representative of the class. CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |